Next Steps for Patient-Centered Drug Development: Room for More Input, With Limits
This article was originally published in Pharmaceutical Approvals Monthly
Patient advocates are pushing FDA to take the next step in the agency’s patient-focused drug development initiative and more directly incorporate the patient experience into regulatory decisions. While that’s a welcomed ask, FDA officials say, it’s not as easy as it looks.
You may also be interested in...
PDUFA V framework to involve patients in the creation of the risk-benefit criteria for various diseases kicks off before the legislation is even enacted.
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.
Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.